Wall Street brokerages expect that Antares Pharma, Inc. (NASDAQ:ATRS) will report earnings per share (EPS) of $0.02 for the current quarter, Zacks Investment Research reports. Four analysts have issued estimates for Antares Pharma’s earnings. The lowest EPS estimate is $0.01 and the highest is $0.02. Antares Pharma reported earnings per share of $0.01 during the same quarter last year, which suggests a positive year over year growth rate of 100%. The business is expected to issue its next earnings report on Thursday, August 5th.
On average, analysts expect that Antares Pharma will report full-year earnings of $0.11 per share for the current year, with EPS estimates ranging from $0.08 to $0.13. For the next year, analysts anticipate that the business will post earnings of $0.25 per share, with EPS estimates ranging from $0.20 to $0.31. Zacks’ earnings per share averages are an average based on a survey of sell-side research analysts that that provide coverage for Antares Pharma.
Antares Pharma (NASDAQ:ATRS) last issued its quarterly earnings data on Wednesday, May 5th. The specialty pharmaceutical company reported $0.02 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.01 by $0.01. Antares Pharma had a net margin of 6.64% and a return on equity of 16.48%.
NASDAQ:ATRS opened at $3.81 on Friday. The firm has a 50 day simple moving average of $3.97 and a 200-day simple moving average of $3.89. The company has a debt-to-equity ratio of 0.53, a current ratio of 2.47 and a quick ratio of 2.08. The firm has a market cap of $643.12 million, a PE ratio of 63.51 and a beta of 1.44. Antares Pharma has a 1-year low of $2.39 and a 1-year high of $5.07.
In other Antares Pharma news, EVP Peter J. Graham sold 45,000 shares of the firm’s stock in a transaction on Thursday, February 18th. The shares were sold at an average price of $4.93, for a total transaction of $221,850.00. Following the completion of the transaction, the executive vice president now directly owns 582,490 shares of the company’s stock, valued at approximately $2,871,675.70. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Thomas J. Garrity sold 50,000 shares of the firm’s stock in a transaction on Thursday, March 11th. The stock was sold at an average price of $4.28, for a total transaction of $214,000.00. Following the transaction, the director now directly owns 274,406 shares of the company’s stock, valued at $1,174,457.68. The disclosure for this sale can be found here. In the last three months, insiders sold 602,281 shares of company stock worth $2,973,021. Insiders own 5.90% of the company’s stock.
Several hedge funds and other institutional investors have recently bought and sold shares of ATRS. Banque Cantonale Vaudoise acquired a new position in shares of Antares Pharma in the 4th quarter valued at about $40,000. Truist Financial Corp acquired a new position in shares of Antares Pharma in the 4th quarter valued at about $48,000. Jane Street Group LLC bought a new stake in Antares Pharma in the 4th quarter valued at about $52,000. Kestra Advisory Services LLC bought a new stake in Antares Pharma in the 4th quarter valued at about $57,000. Finally, Teacher Retirement System of Texas bought a new stake in Antares Pharma in the 4th quarter valued at about $57,000. 39.92% of the stock is owned by institutional investors and hedge funds.
Antares Pharma Company Profile
Antares Pharma, Inc, a specialty pharmaceutical company, focuses primarily on the development and commercialization of pharmaceutical products and technologies that address unmet needs in targeted therapeutic areas. It develops, manufactures, and commercialize novel therapeutic products using its drug delivery systems.
Recommended Story: Dividend Aristocrat Index
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma and related companies with MarketBeat.com's FREE daily email newsletter.